Zobrazeno 1 - 10
of 3 435
pro vyhledávání: '"J, van der Woude"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jürgen Floege, Armin Kurtz
Publikováno v:
Nephrology Dialysis Transplantation. 22:658-659
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24414b52b476f22873e46fdb641582e1
https://doi.org/10.1093/ndt/gfl825
https://doi.org/10.1093/ndt/gfl825
Autor:
J van der Woude, S Schreiber, L Peyrin-Biroulet, Z Szekanecz, E H Choy, P J Stiers, P Van Hoek, K Van Beneden, A de Haas, C Rudolph, H ten Cate
Publikováno v:
Journal of Crohn's and Colitis. 17:i646-i649
Background The once-daily, oral, Janus kinase 1 preferential inhibitor filgotinib (FIL) is approved for the treatment of moderately to severely active rheumatoid arthritis (RA) and ulcerative colitis (UC) in the UK, the EU and Japan.1 To further unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::912daa445de5ea4934b459b16d506285
https://doi.org/10.1093/ecco-jcc/jjac190.0650
https://doi.org/10.1093/ecco-jcc/jjac190.0650
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 13 (2020)
Background and aims: Early prediction of the effect of vedolizumab (VDZ) in inflammatory bowel disease (IBD) is of paramount importance to guide clinical decisions. This study assessed whether early fecal calprotectin (FC) can predict endoscopic resp
Externí odkaz:
https://doaj.org/article/924c781f712d443b84c2e2943d1c9b9c
Autor:
J Jansen, L J T Smits, R W M Pauwels, W Kievit, D J de Jong, A C de Vries, F Hoentjen, C J van der Woude, A.A. van Bodegraven, A.G.L. Bodelier, P.J. Boekema, N. de Boer, P.C.J. ter Borg, A.A. den Broeder, I.A.M Gisbertz, F.M Jansen, S.V. Jansen, D.J. de Jong, W. Kievit, R.C.A. van Linschoten, M Löwenberg, M.W.M.D. Lutgens, R.C. Mallant-Hent, A.E. van der Meulen, B. Oldenburg, R.W.M. Pauwels, M Pierik, M.J.L. Romberg-Camps, T.E.H. Römkens, M.G.V.M. Russel, L.J.T. Smits, A.C.I.T.L. Tan, M.L. Verhulst, A.C. de Vries, R.L. West, F.H.J. Wolfhagen, C.J. van der Woude
Publikováno v:
BMJ Open, Vol 10, Iss 5 (2020)
Introduction Adalimumab is effective for maintenance of remission in patients with Crohn’s disease (CD) at a dose of 40 mg subcutaneously every 2 weeks. However, adalimumab is associated with (long-term) adverse events and is costly. The aim of thi
Externí odkaz:
https://doaj.org/article/137bae053ba5412d9dec48e602f720d7
Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-8 (2017)
Abstract Background The role of single nucleotide polymorphisms (SNPs) associated with inflammatory bowel disease (IBD) is gaining interest. With the advent of novel therapies, personalized treatment in IBD is a future goal. We wondered whether IBD-a
Externí odkaz:
https://doaj.org/article/020e667f106a4ef9a58bdf7631936b9e
Autor:
R. L. Goetgebuer, C. J. van der Woude, L. Bakker, A. A. van der Eijk, L. de Ridder, A. C. de Vries
Publikováno v:
Scandinavian Journal of Gastroenterology, 57(11), 1321-1326. Informa Healthcare
Scandinavian journal of gastroenterology, 57(11), 1321-1326. Informa Healthcare
Scandinavian journal of gastroenterology, 57(11), 1321-1326. Informa Healthcare
Clinical guidelines on cytomegalovirus (CMV) colitis in inflammatory bowel disease (IBD) are hampered by the low quality of evidence. In this study, we aim to explore the attitude and management of CMV colitis in IBD among gastroenterologists. A web-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a3330fc5bdc001bfbd08a06b1d059c
https://pure.eur.nl/en/publications/8863e755-6af3-41f7-9072-9054a9ad73f3
https://pure.eur.nl/en/publications/8863e755-6af3-41f7-9072-9054a9ad73f3
Autor:
Romy van der Groef, Pascal HP de Jong, Dirk Jan Hijnen, Christien J van der Woude, Jan AM van Laar, P Hugo M van der Kuy, Jan-Dietert Brugma, Annelieke Pasma
Publikováno v:
Patient Preference and Adherence, 17, 167-174. Dove Medical Press Ltd.
Romy van der Groef,1 Pascal HP de Jong,1 Dirk Jan Hijnen,2 Christien J van der Woude,3 Jan AM van Laar,4 P Hugo M van der Kuy,5 Jan-Dietert Brugma,6 Annelieke Pasma1 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, the Nethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ab86880bceda22fc16b3ca360a2dd5
https://pure.eur.nl/en/publications/7c17018c-d8e9-44d2-8324-38374f7760ab
https://pure.eur.nl/en/publications/7c17018c-d8e9-44d2-8324-38374f7760ab
Autor:
Renske W. M. Pauwels, Sebastiaan ten Bokkel Huinink, Christien J. van der Woude, M. Doukas, L. Oudijk, Annemarie C. de Vries
Background: Response evaluation after induction therapy with ustekinumab (UST) in Crohn’s disease (CD) is important for decisions on maintenance therapy. We aimed to assess the potential of fecal calprotectin (FC) levels to predict endoscopic respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b5afd7ab9ef096661c785b149ff8150
Publikováno v:
Alimentary Pharmacology & Therapeutics, 57(9), 1030-1031. Wiley-Blackwell Publishing Ltd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbad407962258c34d6db9b173a0555b
https://doi.org/10.1111/apt.17415
https://doi.org/10.1111/apt.17415